Literature DB >> 23100404

Lethal multiple sclerosis relapse after natalizumab withdrawal.

Valérie Rigau1, Alexandre Mania, Patrice Béfort, Bertrand Carlander, Olivier Jonquet, Hans Lassmann, William Camu, Eric Thouvenot.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23100404     DOI： 10.1212/WNL.0b013e318275979d

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  21 in total

1.  Post-natalizumab clinical and radiological findings in a cohort of multiple sclerosis patients: 12-month follow-up.

Authors:  Marta Melis; Eleonora Cocco; Jessica Frau; Lorena Lorefice; Giuseppe Fenu; Giancarlo Coghe; Marco Mura; Maria Giovanna Marrosu
Journal:  Neurol Sci       Date:  2013-08-30       Impact factor: 3.307

Review 2.  [Immunotherapies for multiple sclerosis : review and update].

Authors:  J Havla; T Kümpfel; R Hohlfeld
Journal:  Internist (Berl)       Date:  2015-04       Impact factor: 0.743

Review 3.  Monoclonal antibodies as disease modifying therapy in multiple sclerosis.

Authors:  Erin E Longbrake; Becky J Parks; Anne H Cross
Journal:  Curr Neurol Neurosci Rep       Date:  2013-11       Impact factor: 5.081

4.  Intense immunosuppression for the treatment of an immune reconstitution inflammatory syndrome-like exacerbation after natalizumab withdrawal: a case report.

Authors:  Maria Sepúlveda; Sara Llufriu; Yolanda Blanco; Nuria Solà-Valls; Delon La Puma; Joan Berenguer; Pablo Villoslada; Albert Saiz
Journal:  J Neurol       Date:  2014-11-20       Impact factor: 4.849

5.  Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE.

Authors:  Michael Kaufman; Bruce A C Cree; Jerome De Sèze; Robert J Fox; Ralf Gold; Hans-Peter Hartung; Douglas Jeffery; Ludwig Kappos; Xavier Montalbán; Bianca Weinstock-Guttman; Barry Ticho; Petra Duda; Amy Pace; Denise Campagnolo
Journal:  J Neurol       Date:  2014-11-09       Impact factor: 4.849

6.  Relapse frequency in transitioning from natalizumab to dimethyl fumarate: assessment of risk factors.

Authors:  Jonathan Zurawski; Ashley Flinn; Lindsay Sklover; Jacob A Sloane
Journal:  J Neurol       Date:  2016-05-18       Impact factor: 4.849

7.  Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients.

Authors:  Per Soelberg Sorensen; Nils Koch-Henriksen; Thor Petersen; Mads Ravnborg; Annette Oturai; Finn Sellebjerg
Journal:  J Neurol       Date:  2014-04-12       Impact factor: 4.849

Review 8.  Therapeutic decisions in multiple sclerosis: moving beyond efficacy.

Authors:  Wolfgang Brück; Raff Gold; Brett T Lund; Celia Oreja-Guevara; Alexandre Prat; Collin M Spencer; Lawrence Steinman; Mar Tintoré; Timothy L Vollmer; Martin S Weber; Leslie P Weiner; Tjalf Ziemssen; Scott S Zamvil
Journal:  JAMA Neurol       Date:  2013-10       Impact factor: 18.302

Review 9.  The CD8 T Cell-Epstein-Barr Virus-B Cell Trialogue: A Central Issue in Multiple Sclerosis Pathogenesis.

Authors:  Caterina Veroni; Francesca Aloisi
Journal:  Front Immunol       Date:  2021-07-07       Impact factor: 7.561

Review 10.  Role of regulatory T cells in pathogenesis and biological therapy of multiple sclerosis.

Authors:  Milan Buc
Journal:  Mediators Inflamm       Date:  2013-05-12       Impact factor: 4.711
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.